NasdaqGS - Nasdaq Real Time Price USD

Zevra Therapeutics, Inc. (ZVRA)

8.25

+0.21

+(2.61%)

As of 11:16:35 AM EST. Market Open.

Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. 10 days ago

ZVRA
+2.61%
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long

With the business potentially at an important milestone, we thought we'd take a closer look at Zevra Therapeutics...

Simply Wall St. last month

ZVRA
+2.61%
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) (“NBI”) as part of the annual reconstitution of the 2024 Nasdaq indexes. Zevra’s inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024. “The past year has

GlobeNewswire last month

ZVRA
+2.61%
A drug for fewer than 1,000 patients? Awareness and diagnosis are key.

Zevra Therapeutics is building a commercial strategy for an ultra-small patient pool.

Pharma Voice last month

ZVRA
+2.61%
Zevra Therapeutics Announces Organizational Changes

CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced organizational changes designed to accelerate its transformation into a leading rare disease therapeutics company. The company announced that it is consolidating its development and scientific functions under Adrian Quartel, M.D., FFPM, Chief Medical Officer. Adrian

GlobeNewswire last month

ZVRA
+2.61%
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake

Key Insights Given the large stake in the stock by institutions, Zevra Therapeutics' stock price might be vulnerable to...

Simply Wall St. last month

ZVRA
+2.61%
Zevra Therapeutics to Participate at Upcoming Investor Conferences

CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in the following December investor events. Piper Sandler 36th Annual Healthcare Conference, on Wednesday, December 4, 2024, at 10:30 a.m. ET.Oppenheimer Movers in Rare Disease Sum

GlobeNewswire 2 months ago

ZVRA
+2.61%
Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease

An announcement from Zevra Therapeutics ( (ZVRA) ) is now available. Zevra Therapeutics has announced the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick Disease Type C (NPC). This breakthrough offers a new hope for patients, as it is used in combination with miglustat to treat neurological symptoms in both adults and children. Zevra’s patient support program, AmplifyAssist™, provides essential resources to navigate prescription processes and

TipRanks 2 months ago

ZVRA
+2.61%
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™, Zevra’s comprehensive patient support program, in place to address access barriers CELEBRATION, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that MIPLYFFA™ (MY-PLY-FAH) (arimoclomol), the first treatment approved by the

GlobeNewswire 2 months ago

ZVRA
+2.61%
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report

The analysts might have been a bit too bullish on Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ), given that the company fell...

Simply Wall St. 2 months ago

ZVRA
+2.61%
Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Zevra Therapeutics ( NASDAQ:ZVRA ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.70m (up 28% from 3Q...

Simply Wall St. 2 months ago

ZVRA
+2.61%
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Zevra Therapeutics Inc (ZVRA) reports significant progress with Myle's launch and strategic planning, despite financial setbacks and underperformance of Aprova.

GuruFocus.com 2 months ago

ZVRA
+2.61%
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -56.82% and 26.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ZVRA
+2.61%
Zevra Therapeutics: Q3 Earnings Snapshot

CELEBRATION, Fla. AP) — Zevra Therapeutics, Inc. ZVRA) on Tuesday reported a loss of $33.2 million in its third quarter.

Associated Press Finance 2 months ago

ZVRA
+2.61%
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher Company ends quarter with cash, cash equivalents and investments of $95.5 million Company to host conference call and webcast today, Nov. 12, 2024, 4:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company

GlobeNewswire 2 months ago

ZVRA
+2.61%
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 40% and 0.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ZVRA
+2.61%
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Data show that the NPCCSS swallow score reflects the patient’s level of dysfunction Study indicates that a change in score reflects actual improvement or worsening in a patient’s swallowing function CELEBRATION, Fla., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, N

GlobeNewswire 2 months ago

ZVRA
+2.61%
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

CELEBRATION, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference Virtual on Wednesday, Nov. 13, 2024, at 4 p.m. ET. Additionally, management will be available for

GlobeNewswire 2 months ago

ZVRA
+2.61%
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Company will host conference call at 4:30 p.m. ET that dayCELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024. The Company will issue a news release after the market closes and host a conference call/audio webcast a

GlobeNewswire 2 months ago

ZVRA
+2.61%
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

IONS

ZVRA
+2.61%

Performance Overview

Return	ZVRA	S&P 500
YTD	+0.49%	+1.50%
1-Year	+38.08%	+22.59%
3-Year	+28.50%	+37.83%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Zevra Therapeutics, Inc. (ZVRA)

Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock

Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

A drug for fewer than 1,000 patients? Awareness and diagnosis are key.

Zevra Therapeutics Announces Organizational Changes

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Performance Overview